Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.42 |
| ▸ | DRD3 | P35462 | 10/20 | 0.42 |
| ▸ | VEGFA | P15692 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 6/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4885118 | 0.99 | DRD2 (0.41) | DRD2DRD3VEGFAEGLN1DRD1 | |
| SCHEMBL4179654 | 0.81 | BCHE (0.38) | DRD2DRD3MEN1KMT2A | |
| SCHEMBL3205175 | 0.80 | BCHE (0.37) | NAAA | |
| SCHEMBL3217075 | 0.80 | BCHE (0.37) | NAAA | |
| SCHEMBL4618354 | 0.76 | NAAA (0.38) | NAAA | |
| SCHEMBL4885818 | 0.75 | NAAA (0.36) | DRD3DRD1NAAA | |
| SCHEMBL3201464 | 0.75 | NAAA (0.36) | MEN1KMT2ANAAA | |
| SCHEMBL3222108 | 0.75 | NAAA (0.36) | MEN1KMT2ANAAA | |
| SCHEMBL3224062 | 0.73 | NAAA (0.34) | MAPTNAAA | |
| SCHEMBL4884661 | 0.73 | SIGMAR1 (0.33) | NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | DRD2 308/4885DRD3 392/4885VEGFA 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.